Список литературы

Поставить закладку

Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003;54:3–24.
Arhiri P., Stilidi I.S., Poddubnaya I.V., Nikulin M.P., Tsymzhitova N.Ts., Mazurenko N.N. Clinical significance of mutational status in gastrointestinal stromal tumors (GIST). J Clin Oncol 2012;30(suppl; abstr20501).
Corless C.L., Barnett C.M., Heinrich M.C. Gastrointestinal stromal tumors: Origin and molecular oncology. Nature Reviews Cancer 2011;11(12):865–78.
Lasota J., Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 2006;23:91–1.
Janeway K.A., Kim S.Y., Lodish M., Nosé V., Rustin P., Gaal J., et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 2011;108(1):314. Epub 2010 Dec 20.
Hostein I., Faur N., Primois C., Boury F., Denard J., Emile J.F., et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010;133(1):141.
Miettinen M., Fetsch J.F., Sobin L.H., et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006;30(1):90–6.
Atiq M.A., Davis J.L., Hornick J.L., Dickson B.C., Fletcher C.D.M., Fletcher J.A., et al. Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Mod Pathol 2021;34(1):95.
Søreide K., Sandvik O.M., Søreide J.A., et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol 2016;40:39.
Ma G.L., Murphy J.D., Martinez M.E., Sicklick J.K. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev 2015;24(1):298.
WHO Classification of Tumors Editorial Board. Digestive system tumors. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumors series, 5th ed; vol. 1).
Gold J.S., Gonen M., Gutierrez A., et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10(11):1045–52.
Joensuu H., Vehtari A., Riihimaki J., et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012;13(3):265–74.
Casali P.G., Blay J.Y., Abecassis N., Bajpai J., Bauer S., et al. Gastrointestinal stromal tumors: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2022;33(1):20–33.
Трякин А.А., Бесова Н.С., Волков Н.М., Гладков О.А., Карасева В.В., Сакаева Д.Д. и соавт. Общие принципы проведения противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли, 2023 (том 13), #3s2, стр. 28–41.
NCCN Guidelines Version 1.2023. Soft Tissue Sarcoma.
Rubin B.P., Blanke C.D., Demetri G.D., et al. Protocol for the Examination of Specimens From Patients With Gastrointestinal Stromal Tumor. Arch Pathol Lab Med 2010;134(2):165–70.
Joensuu H. et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts //The lancet oncology. – 2012. – Т. 13. – №. 3. – С. 265-274.
Chakravarty D., Johnson A., Sklar J., Lindeman N.I., Moore K., Ganesan S., et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022;40(11):1231.
Nannini. (2010). Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (Case reports). Oncology Reports, 25(1). doi:10.3892/or_00001049
Farag S., Geus-Oei L.F., van der Graaf W.T., van Coevorden F., Grunhagen D., Reyners A.K.L., et al. Early Evaluation of Response Using ¹⁸F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. J Nucl Med 2018;59(2)194–6. Epub 2017 Sep 28.
NCCN Guidelines Version 1.2023. Gastrointestinal Stromal Tumors.
Стилиди И.С., Архири П.П., Никулин М.П. Хирургическое лечение больных с первичными локализованными и местнораспространенными гастроинтестинальными стромальными опухолями. Вестн. РОНЦ им. Н.Н. Блохина РАМН. 2010;21(1):77–82.
Ohtani H., Maeda K., Noda E., et al. Meta-analysis of laparoscopic and open surgery for gastric gastrointestinal stromal tumor. Anticancer Res 2013;33:5031–41.
Архири П.П., Стилиди И.С., Поддубная И.В. и др. Эффективность хирургического лечения больных с локализованными стромальными опухолями желудочно-кишечного тракта (ЖКТ). Росс. онкологич. журн. 2016;5(21):233–7.
Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70–83.
Miettinen M., Makhlouf H., Sobin L.H., Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477–89.
Gronchi A., Bonvalot S., Poveda Velasco A., Kotasek D., Rutkowski P., Hohenberger P., et al. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. JAMA Surg 2020;155(6):e200397. Epub 2020 Jun 17.
Liu Z., Zhang Y., Yin H., Geng X., Li S., Zhao J., et al. Comparison of Prognosis Between Microscopically Positive and Negative Surgical Margins for Primary Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis. Front Oncol 2022;12:679115. DOI: 10.3389/fonc.2022.679115
Hølmebakk T., Bjerkehagen B., Hompland I., Stoldt S., Boye K. Relationship between R1 resection, tumor rupture and recurrence in resected gastrointestinal stromal tumor. BJS 2019;106:419–26.
Eisenberg B.L., Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465–75.
De Matteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–8.
Rutkowski P., Gronchi A., Hohenberger P., et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol 2013;20:2937–43.
Eisenberg B.L., Harris J., Blanke C.D., et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99:42–7.
Dematteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D.; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373(9669):1097.
Corless C.L., Ballman K.V., Antonescu C., et al. Relation for tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST). Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2010;28(15 Suppl)Abstract 10006.
Joensuu H., Eriksson M., Hatrmann J., et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition. 2011;29(18 Suppl)Abstract LBA1.
Corless C.L., Ballman K.V., Antonescu C.R., et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 2014;32:1563–70.
Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26(4):620–5.
Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, inter-group trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626–32.
Verweij J., Casali P.G., Zalcberg J. Progression free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127–34.
Zalcberg J.R., Verweij J., Casali P.G., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751–7.
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247–53.
Patrikidou A., Chabaud S., Ray-Coquard I., et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol 2013;24:1087–93.
Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24;15:2325–31.
Rutkowski P., Nowecki Z., Nyckowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006;93:304–11.
Стилиди И.С., Архири П.П., Никулин М.П. Хирургическое лечение больных с рецидивными и метастатическими стромальными опухолями желудочно-кишечного тракта. Вопр. онкол. 2011;4(57):508–12.
Du C.Y., Zhou Y., Song C., Wang Y.P., Jie Z.G., He Y.L., et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China. Eur J Cancer 2014;50(10):1772–8. DOI: 10.1016/j.ejca.2014.03.28
Park S.J., Ryu M.H., Ryoo B.Y., Park Y.S., Sohn B.S., Kim H.J., et al. The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses. Ann Surg Oncol 2014;21:4211–7.
Rubió-Casadevall J., Martinez-Trufero J., Garcia-Albeniz X., Calabuig S., Lopez-Pousa A., Del Muro J.G., et al. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS), and the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol 2015:22:2948–57.
Fairweather M., Balachandran V.P., Li G.Z., Bertagnolli M.M., Antonescu C., Tap W., et al. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated with Tyrosine Kinase Inhibitors: A Two Institutional Analysis. Ann Surg 2018;268(2):296–302.
Gronchi A., Fiore M., Miselli F., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007;245:341–6.
DeMatteo R.P., Maki R.G., Singer S., et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007;245:347–52.
Filonenko D.A., Arkhiri P.P., Nikulin M.P., Sagaidak I.V., Yugai V.V., Zhukova L.G., et al. Cytoreductive Surgery in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Sensitive to Imatinib: A retrospective Analysis of Two Russian Cancer Centers. Ann Oncol 2022;33(suppl 4):S318.
Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329–38.
George S., Blay J.Y., Casali P.G., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959–68.
Janeway K.A., Albritton K.H., Van Den Abbeele A.D., D’Amato G.Z., Pedrazzoli P., Siena S., et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 2009;52:767–71.
Katherine A Janeway, Karen H Albritton, Annick D Van Den Abbeele, Gina Z D'Amato, Paolo Pedrazzoli, Salvatore Siena, Joel Picus, James E Butrynski, Marcus Schlemmer, Michael C Heinrich, George D Demetri. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul;52(7):767-71.
Demetri G.D., Reichardt P., Kang Y.K., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):295–302.
Kang Y.K., Ryu M.H., Yoo C., et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013;14:1175–82.
Schöffski P., Reichardt P., Blay J.Y., et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010;21:1990–8.
Drilon A., Laetsch T.W., Kummar S., et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adult and children. N Engl J Med 2018;378:731–9.
Doebele R.C., Drilon A., Paz-Ares L., et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumors: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271–82.
G.S. Falchook, J.C. Trent, M.C. Heinrich, C. Beadling, J. Patterson, C.C. Bastida, S.C. Blackman, R. Kurzrock. BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 2013; 4: 310-315.
Montemurro M., Gelderblom H., Bitz U., et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer 2013;49(5):1027–31.
Park S.H., Ryu M.H., Ryoo B.Y., et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012;30:2377–83.
Schuetze S.M., Bolejack V., Thomas D.G., von Mehren M., Patel S., Samuels B., et al. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 2018;4(6):814.
Montemurro M., Cioffi A., Dômont J., Rutkowski P., Roth A.D., von Moos R., et al. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). Cancer 2018;124(7):1449.
Ganjoo K.N., Villalobos V.M. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol 2014;25(1):236–40.
Mir O., Cropet C., Toulmonde M., Cesne A.L., Molimard M., Bompas E., et al.; PAZOGIST study group of the French Sarcoma Groupe-Groupe d’Etude des Tumeurs Osseuses (GSF-GETO). Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016;17(5):632. Epub 2016 Apr 5.
Schöffski P., Mir O., Kasper B., et al. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’. Eur J Cancer 2020;134:62–74.
Montemurro M., Schöffski P., Reichardt P., et. al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009;45(13):2293–7.
Reichardt P., Blay J.Y., Gelderblom H., Schlemmer M., Demetri G.D., Bui-Nguyen B., et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23(7):1680.
R. Coleman, P. Hadji, J.-J. Body, D. Santini, E. Chow, E. Terpos, S. Oudard, Ø. Bruland, P. Flamen, A. Kurth, C. Van Poznak, M. Aapro & K. Jordan. Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology 2020;31(12):1650-1663.
Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatment related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013;92:715–27.
Luther A., Gabriel J., Watson R.P., Francis N.K. The Impact of Total Body Prehabilitation on Post-Operative Outcomes After Major Abdominal Surgery: A Systematic Review. World J Surg 2018;42(9):2781–91.
Снеговой А.В., Бесова Н.С., Веселов А.В., Кравцов С.А., Ларионова В.Б., Сельчук В.Ю., и др. Практические рекомендации по нутритивной поддержке у онкологических больных. Злокачеств. опухоли. 2016;4(Спецвып. 2):434–50.
Arends J., Bachmann P., Baracos V., Barthelemy N., Bertz H., Bozzetti F., et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017;36:11–48.
Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., et al. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Ann Surg Oncol 2015;22(13):4117–23. DOI: 10.1245/s10434-015-4550-z.
Hijazia Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 2017;39:156–62.
Gemmill E.H., Humes D.J., Catton J.A. Systematic review of enhanced recovery after gastro-oesophageal cancer surgery. Ann R Coll Surg Engl 2015;97:173–9.
Pisarska M., Małczak P., Major P., Wysocki M., Budzyński A., Pędziwiatr M. Enhanced recovery after surgery protocol in oesophageal cancer surgery: Systematic review and meta-analysis. PLoS One 2017;12(3):e0174382.
Feng F., Ji G., Li J.P., Li X.H., Shi H., Zhao Z.W., et al. Fast-track surgery could improve postoperative recovery in radical total gastrectomy patients. World J Gastroenterol 2013;19(23):3642–8.
Souza Possa S., Braga Amador C., Meira Costa A., Takahama Sakamoto E., Seiko Kondo C., Maida Vasconcellos A.L., et al. Implementation of a guideline for physical therapy in the postoperative period of upper abdominal surgery reduces the incidence of atelectasis and length of hospital stay. Rev Port Pneumol 2014;20(2):69–77.
Lewis L.K., Williams M.T., Olds T.S. The active cycle of breathing technique: A systematic review and meta-analysis. Respir Med 2012;106(2):155–72.
Almeida E.P.M., Almeida J.P., Landoni G., Galas F.R.B.G., Fukushima J.T., Fominskiy E., et al. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial. Brit J Anaesth 2017;119(5):900–7.
Mitchinson A.R., Kim H.M., Rosenberg J.M., Geisser M., Kirsh M., Cikrit D., et al. Acute postoperative pain management using massage as an adjuvant therapy. A randomized trial. Arch Surg 2007;142(12):1158–67.
Kukimoto Y., Ooe N., Ideguchi N. The Effects of Massage Therapy on Pain and Anxiety after Surgery: A Systematic Review and Meta-Analysis. Pain Manag Nurs 2017;18(6):378–90.
Swarm R.A., Abernethy A.P., Anghelescu D.L., Benedetti C., Buga S., Cleeland C., et al. Adult cancer pain. J Natl Compr Canc Netw 2013;11(8):992–1022.
Cho I., Son Y., Song S., Bae Y.J., Kim Y.N., Kim H.-I., et al. Feasibility and Effects of a Postoperative Recovery Exercise Program Developed Specifically for Gastric Cancer Patients (PREP-GC) Undergoing Minimally Invasive Gastrectomy. J Gastric Cancer 2018;18(2):118–33.
Shin K.Y., Guo Y., Konzen B., Fu J., Yadav R., Bruera E. Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011;90(5 Suppl_1):S63–8.
Bourke L., Homer K.E., Thaha M.A., Steed L., Rosario D.J., Robb K.A. Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review. Br J Cancer 2014;110:831–41.
Hunter E.G., Baltisberger J. Functional outcomes by age for inpatient cancer rehabilitation: a retrospective chart review. J Appl Gerontol 2013;32(4):443–56.
Грушина Т.И. Реабилитация в онкологии: физиотерапия. М.: ГЭОТАР-Медиа; 2006. 240 с.
Hu C., Zhang H., Wu W., et al. Acupuncture for Pain Management in Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2016;2016:1720239. Epub 2016 Feb 10.
O’Neill L.M., Guinan E., Doyle S.L., Bennett A.E., Murphy C., Elliott J.A., et al. The RESTORE Randomized Controlled Trial Impact of a Multidisciplinary Rehabilitative Program on Cardiorespiratory Fitness in Esophagogastric cancer Survivorship. Ann Surg 2018;268:747–55.
Ajani J.A., D’Amico T.A., Almhanna K., Bentrem D.J., Chao J., Das P., et al. Gastric Cancer. Version 3. 2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016;14(10):1286–312.
Kripp M., Heußer A.L., Belle S., Gerhardt A., Merx K., Hofmann W.K., et al. Does physical activity improve quality of life in cancer patients undergoing chemotherapy? Oncol Res Treat 2015;38(5):230–6.
Mustian K.M., Alfano C.M., Heckler C., et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017;3:961–8.
Bland K.A., Zadravec K., Landry T., Weller S., Meyers L., Campbell K.L. Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol 2019;136:79–85.
Kleckner I.R., Kamen C., Gewandter J.S., et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018;26:1019–28.
Streckmann F., Zopf E.M., Lehmann H.C., et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44:1289–304.
Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018;10(Suppl_35):S4391–9.
Kinkead B., Schettler P.J., Larson E.R., Carroll D., Sharenko M., Nettles J., et al. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer 2018;124(3):546–54.
Lee J.M., Look R.M., Turner C., Gardiner S.K., Wagie T., Douglas J., et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012; 30(15_suppl):9019-9019.
Rick O., von Hehn U., Mikus E., Dertinger H., Geiger G. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2016;38(2):85–94.
Kılınç M., Livanelioğlu A., Yıldırım S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014;46(5):454–60.
Oberoi S., Zamperlini-Netto G., Beyene J., Treister N.S., Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014;9(9):e107418.
Guo W.C., Wang F. Effect of nerve electrical stimulation for treating chemotherapy-induced nausea and vomiting in patients with advanced gastric cancer: A randomized controlled trial. Medicine (Baltimore) 2018;97(51):e13620.
Ross M., Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs 2017;21(2):226–33.
D’Ambrosio L., Palesandro E., Boccone P., et al. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. Eur J Cancer 2017;78:122–32.
Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649−55.
Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C. (ed.). Evaluation of chemotherapeutic agents. NY: Columbia University Press; 1949:191–205.
Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026
Hawker G.A., Mian S., Kendzerska T., French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. (Hoboken) 2011;63(Suppl 11):S240–52.
Reddy R. M., Fleshman J. W. Colorectal gastrointestinal stromal tumors: a brief review //Clinics in colon and rectal surgery. – 2006. – Т. 19. – №. 02. – С. 069-077.
Vernuccio F. et al. Imaging of gastrointestinal stromal tumors: from diagnosis to evaluation of therapeutic response //Anticancer research. – 2016. – Т. 36. – №. 6. – С. 2639-2648.